Digital Exclusives
A new breed of price gouging pharmaceutical companies is facing public outrage from consumers—and spurring discourse on drug pricing in the process.
Ari Friedman and Janet Weiner of the Leonard Davis Institute of Health Economics discuss drug prices, their rising costs, and the policy changes that could provide solutions.
